Daewoong Pharmaceutical's botulinum toxin drug Nabota exceeded $100 million in cumulative sales in North America this year. This is an increase of 61% compared to the previous year. According to the earnings report of Daewoong Pharmaceutical partner Evolus on the 9th (local time), Jeuveau, which is sold by the company, recorded cumulative sales of $13.6 million (14.3 billion won) in the third quarter of this year, up 61.1% from a year earlier. Jeuveau is the North American product name of Nabota, a botulinum toxin formulation exported by Daewoong Pharmaceutical. Sales in the third quarter were $33.21 million (45.6 billion won), the lowest this year, but increased by 24.5% compared to the same period last year.